Spots Global Cancer Trial Database for recurrent bladder cancer
Every month we try and update this database with for recurrent bladder cancer cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| OGX-011 and Docetaxel in Treating Patients With Metastatic or Locally Recurrent Solid Tumors | NCT00471432 | Bladder Cancer Breast Cancer Kidney Cancer Lung Cancer Ovarian Cancer Prostate Cancer Unspecified Adu... | custirsen sodiu... docetaxel pharmacological... | 18 Years - 120 Years | Canadian Cancer Trials Group | |
| S0031, ZD 1839 in Treating Patients With Advanced Cancer of the Urinary Tract | NCT00014144 | Bladder Cancer Transitional Ce... Urethral Cancer | gefitinib | - | SWOG Cancer Research Network | |
| Bortezomib in Treating Patients With Advanced or Metastatic Transitional Cell Cancer of the Bladder, Renal Pelvis, or Ureter | NCT00066352 | Bladder Cancer Transitional Ce... | bortezomib | 18 Years - | University Health Network, Toronto | |
| AD 32 With or Without BCG After Surgery in Treating Patients With Newly Diagnosed or Recurrent Superficial Bladder Cancer | NCT00003759 | Bladder Cancer | BCG vaccine valrubicin conventional su... | 18 Years - | National Cancer Institute (NCI) | |
| Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic Cancer | NCT00005842 | Cancer | trastuzumab tipifarnib | 18 Years - | National Cancer Institute (NCI) | |
| Family Caregiver Palliative Care Intervention in Supporting Caregivers of Patients With Stage II-IV Gastrointestinal, Gynecologic, Urologic and Lung Cancers | NCT01846520 | Healthy Subject Localized Trans... Metastatic Tran... Psychosocial Ef... Recurrent Bladd... Recurrent Cervi... Recurrent Colon... Recurrent Gastr... Recurrent Ovari... Recurrent Ovari... Recurrent Pancr... Recurrent Recta... Recurrent Renal... Recurrent Trans... Recurrent Ureth... Recurrent Uteri... Regional Transi... Stage II Bladde... Stage II Renal ... Stage II Urethr... Stage IIA Cervi... Stage IIA Colon... Stage IIA Gastr... Stage IIA Ovari... Stage IIA Ovari... Stage IIA Pancr... Stage IIA Recta... Stage IIA Uteri... Stage IIB Cervi... Stage IIB Colon... Stage IIB Gastr... Stage IIB Ovari... Stage IIB Ovari... Stage IIB Pancr... Stage IIB Recta... Stage IIB Uteri... Stage IIC Colon... Stage IIC Ovari... Stage IIC Ovari... Stage IIC Recta... Stage III Bladd... Stage III Pancr... Stage III Renal... Stage III Ureth... Stage IIIA Cerv... Stage IIIA Colo... Stage IIIA Gast... Stage IIIA Ovar... Stage IIIA Ovar... Stage IIIA Rect... Stage IIIA Uter... Stage IIIB Cerv... Stage IIIB Colo... Stage IIIB Gast... Stage IIIB Ovar... Stage IIIB Ovar... Stage IIIB Rect... Stage IIIB Uter... Stage IIIC Colo... Stage IIIC Gast... Stage IIIC Ovar... Stage IIIC Ovar... Stage IIIC Rect... Stage IIIC Uter... Stage IV Bladde... Stage IV Gastri... Stage IV Ovaria... Stage IV Ovaria... Stage IV Pancre... Stage IV Renal ... Stage IV Urethr... Stage IVA Cervi... Stage IVA Colon... Stage IVA Recta... Stage IVA Uteri... Stage IVB Cervi... Stage IVB Colon... Stage IVB Recta... Stage IVB Uteri... Ureter Cancer Stage IIA Lung ... Stage IIB Lung ... Stage IIIA Lung... Stage IIIB Lung... | educational int... telephone-based... quality-of-life... questionnaire a... | 18 Years - | City of Hope Medical Center | |
| S0306, Irinotecan in Treating Patients With Recurrent or Refractory Advanced Transitional Cell Cancer of the Urothelium Previously Treated With Chemotherapy | NCT00066612 | Bladder Cancer Transitional Ce... Urethral Cancer | irinotecan hydr... | 18 Years - | SWOG Cancer Research Network | |
| 3-Dimensional Conformal Radiation Therapy in Treating Patients With Bladder Cancer Who Have Undergone Transurethral Resection of the Bladder | NCT01124682 | Bladder Cancer | diagnostic cyst... diffusion-weigh... implanted fiduc... quality-of-life... 3-dimensional c... image-guided ra... selective exter... | 18 Years - | National Cancer Institute (NCI) | |
| Surgery With or Without Chemotherapy in Treating Patients With Newly Diagnosed or Recurrent Bladder Cancer | NCT00003725 | Bladder Cancer | valrubicin conventional su... | 18 Years - | National Cancer Institute (NCI) | |
| Cystoscopy and Hexyl 5-Aminolevulinate in Detecting Carcinoma In Situ in Patients With Bladder Cancer | NCT00052637 | Bladder Cancer | hexaminolevulin... biopsy cystoscopy | 18 Years - | Photocure | |
| Sunitinib as Second-Line Therapy in Treating Patients With Locally Advanced or Metastatic Transitional Cell Cancer | NCT00792025 | Bladder Cancer Transitional Ce... | sunitinib malat... | 18 Years - | National Cancer Institute (NCI) | |
| S0337, Gemcitabine After Surgery in Treating Patients With Newly Diagnosed or Recurrent Bladder Cancer | NCT00445601 | Bladder Cancer | gemcitabine hyd... placebo | 18 Years - 120 Years | SWOG Cancer Research Network | |
| An Expanded Access Study of Bemarituzumab (FPA144) for a Single Patient With Recurrent Bladder Cancer | NCT03801278 | Recurrent Bladd... | FPA144 | 18 Years - | Five Prime Therapeutics, Inc. | |
| Suramin in Treating Patients With Recurrent Bladder Cancer | NCT00006476 | Bladder Cancer | suramin conventional su... | 18 Years - | National Cancer Institute (NCI) | |
| Intravenous VEGF Trap in Treating Patients With Relapsed or Refractory Advanced Solid Tumors or Non-Hodgkin's Lymphoma | NCT00082823 | Cancer | ziv-aflibercept | 18 Years - 120 Years | Regeneron Pharmaceuticals | |
| Sunitinib Malate in Treating Patients With Locally Recurrent, Locally Advanced, Unresectable, or Metastatic Urinary Tract Cancer | NCT01118039 | Bladder Cancer Transitional Ce... Urethral Cancer | sunitinib malat... immunohistochem... laboratory biom... pharmacological... quality-of-life... | 18 Years - | National Cancer Institute (NCI) | |
| Loop Resectoscope in Treating Patients With Bladder Cancer or Benign Prostatic Hyperplasia Who Are Undergoing Transurethral Resection | NCT00303654 | Bladder Cancer | biopsy therapeutic con... | - | National Cancer Institute (NCI) | |
| Gemcitabine, Paclitaxel, Doxorubicin in Metastatic or Unresectable Bladder Cancer With Decreased Kidney Function | NCT00478361 | Distal Urethral... Metastatic Tran... Proximal Urethr... Recurrent Bladd... Recurrent Trans... Recurrent Ureth... Regional Transi... Stage III Bladd... Stage IV Bladde... Transitional Ce... Urethral Cancer... | Gemcitabine hyd... Paclitaxel Doxorubicin hyd... Pegfilgrastim | - | M.D. Anderson Cancer Center | |
| Massage Therapy in Treating the Symptoms of Patients With Locally Advanced or Metastatic Cancer | NCT00253708 | Cancer | management of t... massage therapy pain therapy psychosocial as... quality-of-life... | 18 Years - 120 Years | Beth Israel Deaconess Medical Center | |
| Docetaxel and St. John's Wort in Treating Patients With Solid Tumors That Cannot Be Removed By Surgery | NCT00041171 | Adult Solid Tum... Breast Cancer Head and Neck C... Kidney and Urin... Male Reproducti... Thorax and Resp... | Hypericum perfo... docetaxel placebo | 18 Years - 120 Years | Alliance for Clinical Trials in Oncology | |
| Pazopanib in Treating Patients With Metastatic Urothelial Cancer | NCT00471536 | Distal Urethral... Proximal Urethr... Recurrent Bladd... Recurrent Trans... Recurrent Ureth... Stage IV Bladde... Transitional Ce... Urethral Cancer... | pazopanib hydro... | 18 Years - | National Cancer Institute (NCI) | |
| Irinotecan Plus Gemcitabine in Treating Patients With Unresectable or Metastatic Solid Tumors | NCT00004095 | Bladder Cancer Breast Cancer Colorectal Canc... Kidney Cancer Lung Cancer Pancreatic Canc... | gemcitabine hyd... irinotecan hydr... | 18 Years - 120 Years | Northwestern University | |
| Docetaxel in Treating Patients With Solid Tumors | NCT00003565 | Bladder Cancer Breast Cancer Head and Neck C... Lung Cancer Unspecified Adu... | docetaxel | 18 Years - | Alliance for Clinical Trials in Oncology | |
| BCG Plus Interferon Alfa 2b in Treating Patients With Bladder Cancer | NCT00004122 | Bladder Cancer | BCG vaccine recombinant int... | 18 Years - | Roswell Park Cancer Institute | |
| Cisplatin, Bevacizumab, and Gemcitabine Followed by Surgery, Bevacizumab, and Paclitaxel in Treating Patients With Locally Advanced Nonmetastatic Bladder Cancer That Can Be Removed By Surgery | NCT00268450 | Bladder Cancer | bevacizumab cisplatin gemcitabine hyd... paclitaxel cysectomy | 18 Years - 120 Years | Medical University of South Carolina | |
| Decitabine in Treating Patients With Advanced Solid Tumors | NCT00030615 | Male Breast Can... Recurrent Bladd... Recurrent Breas... Recurrent Melan... Stage III Melan... Stage IV Bladde... Stage IV Breast... Stage IV Melano... Unspecified Adu... | decitabine pharmacological... laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| BCG Plus Interferon Alfa 2b in Treating Patients With Bladder Cancer | NCT00004122 | Bladder Cancer | BCG vaccine recombinant int... | 18 Years - | Roswell Park Cancer Institute | |
| Fluorouracil, Leucovorin, Gemcitabine, and Cisplatin in Treating Patients With Metastatic or Unresectable Adenocarcinoma of the Urothelium or Urachal Remnant | NCT00082706 | Bladder Cancer Urethral Cancer Urachal Cancer | 5-Fluorouracil ... Leucovorin Cisplatin Gemcitabine | 18 Years - | M.D. Anderson Cancer Center | |
| An Expanded Access Study of Bemarituzumab (FPA144) for a Single Patient With Recurrent Bladder Cancer | NCT03801278 | Recurrent Bladd... | FPA144 | 18 Years - | Five Prime Therapeutics, Inc. | |
| Sorafenib in Treating Patients With Regional or Metastatic Cancer of the Urothelium | NCT00112905 | Adenocarcinoma ... Distal Urethral... Metastatic Tran... Proximal Urethr... Recurrent Bladd... Recurrent Trans... Recurrent Ureth... Regional Transi... Squamous Cell C... Stage III Bladd... Stage IV Bladde... Transitional Ce... Urethral Cancer... | sorafenib tosyl... laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Broccoli Sprout Extract in Treating Patients With Transitional Cell Bladder Cancer Undergoing Surgery | NCT01108003 | Recurrent Bladd... Stage 0 Bladder... Stage I Bladder... Stage II Bladde... Transitional Ce... | broccoli sprout... laboratory biom... Mango Juice | 18 Years - | Roswell Park Cancer Institute | |
| Irinotecan Plus Gemcitabine in Treating Patients With Unresectable or Metastatic Solid Tumors | NCT00004095 | Bladder Cancer Breast Cancer Colorectal Canc... Kidney Cancer Lung Cancer Pancreatic Canc... | gemcitabine hyd... irinotecan hydr... | 18 Years - 120 Years | Northwestern University | |
| Cisplatin, Bevacizumab, and Gemcitabine Followed by Surgery, Bevacizumab, and Paclitaxel in Treating Patients With Locally Advanced Nonmetastatic Bladder Cancer That Can Be Removed By Surgery | NCT00268450 | Bladder Cancer | bevacizumab cisplatin gemcitabine hyd... paclitaxel cysectomy | 18 Years - 120 Years | Medical University of South Carolina | |
| Ixabepilone in Treating Patients With Advanced Urinary Tract Cancer | NCT00021099 | Distal Urethral... Metastatic Tran... Proximal Urethr... Recurrent Bladd... Recurrent Trans... Recurrent Ureth... Regional Transi... Stage III Bladd... Stage IV Bladde... Transitional Ce... Urethral Cancer... | ixabepilone | 18 Years - | National Cancer Institute (NCI) | |
| AD 32 With or Without BCG After Surgery in Treating Patients With Newly Diagnosed or Recurrent Superficial Bladder Cancer | NCT00003759 | Bladder Cancer | BCG vaccine valrubicin conventional su... | 18 Years - | National Cancer Institute (NCI) | |
| BCG With or Without Gefitinib in Treating Patients With High-Risk Bladder Cancer | NCT00352079 | Bladder Cancer | BCG vaccine gefitinib quality-of-life... | 18 Years - 120 Years | Canadian Cancer Trials Group | |
| Chemotherapy Plus Radiation Therapy in Treating Patients With Unresectable, Residual, or Recurrent Colorectal Cancer | NCT00003704 | Cancer | capecitabine radiation thera... | 18 Years - | Alliance for Clinical Trials in Oncology | |
| Sorafenib in Treating Patients With Regional or Metastatic Cancer of the Urothelium | NCT00112905 | Adenocarcinoma ... Distal Urethral... Metastatic Tran... Proximal Urethr... Recurrent Bladd... Recurrent Trans... Recurrent Ureth... Regional Transi... Squamous Cell C... Stage III Bladd... Stage IV Bladde... Transitional Ce... Urethral Cancer... | sorafenib tosyl... laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic Cancer | NCT00005842 | Cancer | trastuzumab tipifarnib | 18 Years - | National Cancer Institute (NCI) | |
| Efficacy of Combination of Trastuzumab to Gemcitabine - Platinum Advanced or Metastatic Urothelial Carcinoma | NCT01828736 | Recurrent Bladd... Stage IV Bladde... Transitional Ce... | Trastuzumab Gemcitabine Carboplatin Cisplatin | 18 Years - 80 Years | Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie | |
| RAV12 in Treating Patients With Metastatic or Recurrent Adenocarcinoma | NCT00101972 | Cancer | monoclonal anti... | 18 Years - | MacroGenics | |
| Combination Chemotherapy Plus Filgrastim in Treating Patients With Locally Recurrent or Advanced Urothelium Cancer | NCT00005958 | Bladder Cancer Transitional Ce... | filgrastim docetaxel gemcitabine hyd... | 18 Years - | National Cancer Institute (NCI) | |
| Sunitinib Malate in Treating Patients With Locally Recurrent, Locally Advanced, Unresectable, or Metastatic Urinary Tract Cancer | NCT01118039 | Bladder Cancer Transitional Ce... Urethral Cancer | sunitinib malat... immunohistochem... laboratory biom... pharmacological... quality-of-life... | 18 Years - | National Cancer Institute (NCI) | |
| Combination Chemotherapy Plus Filgrastim in Treating Patients With Locally Recurrent or Advanced Urothelium Cancer | NCT00005958 | Bladder Cancer Transitional Ce... | filgrastim docetaxel gemcitabine hyd... | 18 Years - | National Cancer Institute (NCI) | |
| BCG With or Without Mitomycin in Treating Patients With Bladder Cancer | NCT00023842 | Bladder Cancer | BCG vaccine mitomycin C adjuvant therap... conventional su... | - | European Organisation for Research and Treatment of Cancer - EORTC | |
| Gemcitabine and Irinotecan in Treating Patients With Locally Advanced or Metastatic Bladder Cancer | NCT00089128 | Bladder Cancer | gemcitabine hyd... irinotecan hydr... | 18 Years - 120 Years | Medical University of South Carolina | |
| Efficacy of Combination of Trastuzumab to Gemcitabine - Platinum Advanced or Metastatic Urothelial Carcinoma | NCT01828736 | Recurrent Bladd... Stage IV Bladde... Transitional Ce... | Trastuzumab Gemcitabine Carboplatin Cisplatin | 18 Years - 80 Years | Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie | |
| LMB-9 Immunotoxin in Treating Patients With Advanced Solid Tumors | NCT00019435 | Bladder Cancer Breast Cancer Colorectal Canc... Esophageal Canc... Gastric Cancer Lung Cancer Pancreatic Canc... | LMB-9 immunotox... | 18 Years - | National Cancer Institute (NCI) | |
| Gene Therapy in Treating Patients With Advanced Bladder Cancer | NCT00003167 | Recurrent Bladd... Stage I Bladder... Stage II Bladde... Stage III Bladd... Stage IV Bladde... Transitional Ce... | Ad5CMV-p53 gene | 18 Years - | National Cancer Institute (NCI) | |
| A Study of Oral Erdafitinib in People With Recurrent Non-Invasive Bladder Cancer | NCT04917809 | Bladder Cancer Recurrent Bladd... FGFR3 Gene Muta... | Erdafitinib | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Combination Chemotherapy in Treating Patients With Advanced Cancer of the Urothelium and Decreased Kidney Function | NCT00005644 | Bladder Cancer Transitional Ce... Urethral Cancer | gemcitabine hyd... paclitaxel | 18 Years - 120 Years | Eastern Cooperative Oncology Group | |
| 3 Tesla MRI in Patients With Bladder Cancer | NCT00938145 | Bladder Cancer | Specimen Ultra-... chemotherapy Cystectomy and ... | 18 Years - | University of Cincinnati | |
| Intravenous VEGF Trap in Treating Patients With Relapsed or Refractory Advanced Solid Tumors or Non-Hodgkin's Lymphoma | NCT00083213 | Cancer | ziv-aflibercept | 18 Years - 120 Years | Regeneron Pharmaceuticals | |
| Fluorouracil in Treating Patients With Recurrent or Metastatic Bladder Cancer | NCT00003175 | Bladder Cancer Transitional Ce... Urethral Cancer | fluorouracil | - | National Cancer Institute (NCI) | |
| Docetaxel and Lapatinib in Metastatic Transitional Cell Carcinoma in Bladder | NCT01382706 | Recurrent Bladd... Stage III Bladd... Stage IV Bladde... Transitional Ce... | docetaxel lapatinib ditos... immunohistochem... fluorescence in... laboratory biom... | 18 Years - | University of Southern California | |
| Fluorouracil, Leucovorin, Gemcitabine, and Cisplatin in Treating Patients With Metastatic or Unresectable Adenocarcinoma of the Urothelium or Urachal Remnant | NCT00082706 | Bladder Cancer Urethral Cancer Urachal Cancer | 5-Fluorouracil ... Leucovorin Cisplatin Gemcitabine | 18 Years - | M.D. Anderson Cancer Center | |
| LMB-9 Immunotoxin in Treating Patients With Advanced Colon, Breast, Non-small Cell Lung, Bladder, Pancreatic, or Ovarian Cancer | NCT00005858 | Bladder Cancer Breast Cancer Colorectal Canc... Lung Cancer Ovarian Cancer Pancreatic Canc... | LMB-9 immunotox... | 18 Years - | University of Maryland, Baltimore | |
| Afatinib in Advanced Refractory Urothelial Cancer | NCT02122172 | Distal Urethral... Proximal Urethr... Recurrent Bladd... Recurrent Ureth... Stage III Bladd... Stage III Ureth... Stage IV Bladde... Stage IV Urethr... Ureter Cancer | afatinib dimale... laboratory biom... | 18 Years - | University of Chicago | |
| High-Dose Multivitamins Compared to a Placebo in Preventing the Recurrence of Cancer in Patients With Early Stage Bladder Cancer | NCT00003623 | Bladder Cancer | multivitamin Placebo | 18 Years - | Alliance for Clinical Trials in Oncology | |
| Gemcitabine Hydrochloride, Cisplatin, and Sunitinib Malate as First-Line Therapy in Treating Patients With Locally Advanced And/or Metastatic Transitional Cell Carcinoma of the Urothelium (SUCCINCT) | NCT01089088 | Bladder Cancer Transitional Ce... Urethral Cancer | cisplatin gemcitabine hyd... sunitinib malat... | 16 Years - 120 Years | Cardiff University | |
| Chemotherapy Plus Radiation Therapy in Treating Patients With Unresectable, Residual, or Recurrent Colorectal Cancer | NCT00003704 | Cancer | capecitabine radiation thera... | 18 Years - | Alliance for Clinical Trials in Oncology | |
| Biomarkers in Patients With Kidney Cancer or Cancer of the Urothelium and in Healthy Participants | NCT00900276 | Bladder Cancer Kidney Cancer Transitional Ce... Urethral Cancer | immunologic tec... laboratory biom... mass spectromet... | 18 Years - 120 Years | Wake Forest University Health Sciences | |
| Docetaxel and Gemcitabine in Treating Patients With Progressive Regional or Metastatic Bladder Cancer | NCT00004223 | Bladder Cancer Transitional Ce... Urethral Cancer | docetaxel gemcitabine hyd... | 18 Years - 120 Years | Eastern Cooperative Oncology Group | |
| Loop Resectoscope in Treating Patients With Bladder Cancer or Benign Prostatic Hyperplasia Who Are Undergoing Transurethral Resection | NCT00303654 | Bladder Cancer | biopsy therapeutic con... | - | National Cancer Institute (NCI) | |
| Decitabine in Treating Patients With Advanced Solid Tumors | NCT00030615 | Male Breast Can... Recurrent Bladd... Recurrent Breas... Recurrent Melan... Stage III Melan... Stage IV Bladde... Stage IV Breast... Stage IV Melano... Unspecified Adu... | decitabine pharmacological... laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Gemcitabine Hydrochloride, Cisplatin, and Temsirolimus as First-Line Therapy in Treating Patients With Locally Advanced and/or Metastatic Transitional Cell Cancer of the Urothelium | NCT01090466 | Bladder Cancer Transitional Ce... Urethral Cancer | cisplatin gemcitabine hyd... temsirolimus pharmacological... | 16 Years - 120 Years | Cardiff University | |
| S0337, Gemcitabine After Surgery in Treating Patients With Newly Diagnosed or Recurrent Bladder Cancer | NCT00445601 | Bladder Cancer | gemcitabine hyd... placebo | 18 Years - 120 Years | SWOG Cancer Research Network | |
| Combination Chemotherapy in Treating Patients With Advanced Cancer of the Urothelium and Decreased Kidney Function | NCT00005644 | Bladder Cancer Transitional Ce... Urethral Cancer | gemcitabine hyd... paclitaxel | 18 Years - 120 Years | Eastern Cooperative Oncology Group | |
| Sorafenib in Treating Patients With Advanced or Metastatic Cancer of the Urinary Tract | NCT00112671 | Metastatic Tran... Recurrent Bladd... Recurrent Trans... Regional Transi... Stage III Bladd... Stage IV Bladde... Transitional Ce... | sorafenib tosyl... laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Surgery With or Without Chemotherapy in Treating Patients With Newly Diagnosed or Recurrent Bladder Cancer | NCT00003725 | Bladder Cancer | valrubicin conventional su... | 18 Years - | National Cancer Institute (NCI) | |
| BCG With or Without Mitomycin in Treating Patients With Bladder Cancer | NCT00023842 | Bladder Cancer | BCG vaccine mitomycin C adjuvant therap... conventional su... | - | European Organisation for Research and Treatment of Cancer - EORTC | |
| SCH 66336 Plus Gemcitabine in Treating Patients With Advanced Cancer of the Urinary Tract | NCT00006351 | Bladder Cancer Transitional Ce... Urethral Cancer | gemcitabine hyd... lonafarnib | 18 Years - | European Organisation for Research and Treatment of Cancer - EORTC | |
| Pemetrexed Disodium and Gemcitabine in Treating Patients With Advanced Cancer of the Urothelium | NCT00053209 | Bladder Cancer Transitional Ce... Urethral Cancer | gemcitabine hyd... pemetrexed diso... | 18 Years - 120 Years | Eastern Cooperative Oncology Group | |
| Pazopanib Hydrochloride in Treating Patients With Metastatic Urethral Cancer or Bladder Cancer That Has Relapsed or Not Responded to Treatment | NCT01031875 | Bladder Cancer Transitional Ce... Urethral Cancer | pazopanib hydro... fludeoxyglucose... | 18 Years - | National Cancer Institute (NCI) | |
| Cisplatin, Bevacizumab, and Gemcitabine Followed by Surgery, Bevacizumab, and Paclitaxel in Treating Patients With Locally Advanced Nonmetastatic Bladder Cancer That Can Be Removed By Surgery | NCT00268450 | Bladder Cancer | bevacizumab cisplatin gemcitabine hyd... paclitaxel cysectomy | 18 Years - 120 Years | Medical University of South Carolina | |
| Sunitinib in Treating Patients With Progressive Metastatic Transitional Cell Cancer of the Urothelium | NCT00397488 | Bladder Cancer Transitional Ce... Urethral Cancer | sunitinib malat... | 18 Years - 120 Years | Memorial Sloan Kettering Cancer Center | |
| Combination Chemotherapy in Treating Patients With Metastatic or Locally Advanced Bladder Cancer | NCT00003105 | Bladder Cancer Transitional Ce... | filgrastim cisplatin doxorubicin hyd... gemcitabine hyd... ifosfamide paclitaxel | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Afatinib in Advanced Refractory Urothelial Cancer | NCT02122172 | Distal Urethral... Proximal Urethr... Recurrent Bladd... Recurrent Ureth... Stage III Bladd... Stage III Ureth... Stage IV Bladde... Stage IV Urethr... Ureter Cancer | afatinib dimale... laboratory biom... | 18 Years - | University of Chicago | |
| Gene Therapy in Treating Patients With Cancer | NCT00004178 | Cancer | therapeutic aut... | 18 Years - | Roger Williams Medical Center | |
| Chemotherapy With or Without Surgery in Treating Patients With Bladder Cancer | NCT00042887 | Bladder Cancer | mitomycin C conventional su... | - 80 Years | European Organisation for Research and Treatment of Cancer - EORTC |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
